5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results
| Autor: | Burris, H., III, Vukelja, S., Krop, I., Modi, S., Klencke, B., Girish, S., Sliwkowski, M.X., Dresser, M., Phillips, G.L., Rugo, H. |
|---|---|
| Zdroj: | In EJC Supplements 2009 7(2):266-267 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect